Find a pharmacy Healthcare professionals Partnering Press
TR EN RU AR
My Product Is Safe Look up the batch number printed on your box. Only food supplement batches can be queried.
Contact
Tablets on the conveyor of a solid dosage manufacturing line
Since 1989 · Ankara

The manufacturing behind access to medicines in Türkiye.

We have been manufacturing in Ankara since 1989. Six medicines authorised in Türkiye and nine products in R&D, across five therapy areas — principally urology, nephrology and immunology.

Our medicines
MedicinesProduct information, SmPC and package leaflet → Consumer healthOur food supplement products → Report a side effectSpeak to your doctor or pharmacist first →
Aymed at a glance

Specific product groups, an expanding development pipeline.

6
medicines authorised and marketed in Türkiye
9
marketing authorisation applications under way
500 g – 500 kg
batch size range at a single site
50%
of the electricity used at our site comes from our rooftop solar plant
Our therapy areas

We work in five therapy areas and build depth in each of them.

Our medicines and our marketing authorisation applications are concentrated in five therapy areas. Select an area to see the work under way there.

Urology

The company's first products were developed for kidney stones and bladder health, and urology still accounts for the largest part of our portfolio.

Authorised medicines

  • Urocit-Kpotassium citrate · 5/10/15 mEq
  • Elmironpentosan polysulfate sodium · 100 mg
  • Precoxinlidocaine hydrochloride · 10% · 40 mL

Marketing authorisation applications

  • 1 programmeat development or authorisation stage
Aymed İlaç manufacturing site: the building and entrance facade at Başkent OSB
Aymed İlaç has operated in Ankara since 1989.
About us

Access to medicines guides how we choose our development programmes.

We have been manufacturing in Ankara since 1989. Today, with more than 100 employees, a manufacturing site holding a GMP certificate issued by TİTCK and a growing pipeline, we are a manufacturer focused on a small number of therapy areas within the Turkish pharmaceutical industry. Bringing medicines that were not previously available in Türkiye to the Turkish market through domestic manufacturing, under our own authorisations and under licence from established global pharmaceutical companies, has been our core business since the company was founded.

1989founded
100+employees
2sites · Ankara
My Product Is Safe

See the production record of the pack in your hand.

By scanning the code on your product with your phone or entering it manually, you can reach that batch’s production date, expiry date and directions for use.

The look-up applies to our authorised products on the market. No app download, registration or personal detail is required. No personal data is collected during the query.

See how it works →
1 · ScanScan the data matrix code on the pack with your phone camera.
2 · See the batchThe production date and time, batch number and expiry date appear on screen.
3 · See the directionsThe directions for using the product are displayed.
For healthcare professionals and partners

The sections below describe our development pipeline and contract manufacturing services. Information addressed to consumers is in the sections above.

Research and development

What is next in our pipeline?

9marketing authorisation applications
2with a Phase 3 programme under way
7under regulatory review

Note: The products in this section are at the development and marketing authorisation stage. None of them is authorised yet and none is available on the market.

Which areas are the applications in?

  • 3Immunology
  • 2Oncology and haematology
  • 2Nephrology
  • 1Urology
  • 1Metabolic and rare diseases
>
Solar power plant panels on the roof of the manufacturing site
Contract development and manufacturing

We take on commercial manufacturing for products that have completed development, and formulation development on a project basis. Much of the electricity used in our production comes from renewable sources.

Every step from granulation to packaging is carried out at our site in Ankara, and the same equipment train runs from a 500-gram development trial to a 500-kilogram final blend. About half of the electricity used at the site is generated by the solar plant on our roof; on-site generation lowers the emissions attributable to production here, which customers working with supplier-specific data can reflect in their own Scope 3 category 1 reporting.

Capability information for business partners. Not an offer.

50%of site electricity from solar
Capability Matrix

Which services do we provide for which dosage forms?

Find the dosage form in the row and the service in the column. Click a cell for the detail. All capabilities are described on the Manufacturing and Quality Capabilities page.

Contract manufacturing capabilities by dosage form and service
Select a cell

Click the cell where a dosage form meets a service to see the capability detail.

Request a proposal
● full capability◐ project based– out of scope
Press Room

News from the company

Multi-counting system and line operator on the bottle filling line

Our AYM-B02 and AYM-B03 programmes reached Phase 3

Clinical development has reached Phase 3 in two of our biological product programmes in immunology.

Read more →
Capsule packaging on the blister line

Bioequivalence studies completed in five programmes

Bioequivalence studies have been completed for the AYM-201, AYM-202, AYM-204, AYM-205 and AYM-206 programmes; stability studies are ongoing.

Read more →
Solar panels on the manufacturing site roof

Our rooftop solar plant completed its first full year

Over a one-year period, about half of our production electricity came from the rooftop panels.

Read more →
Careers

Making medicines is teamwork.

Open positions

Let us talk about working together.

Email us about partnership Contact us